^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NK cell stimulant

    Related drugs:
    Apply
    QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790)
    Phase 1/2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/24/2025
    Initiation :
    12/01/2017
    Primary completion :
    01/01/2019
    Completion :
    12/23/2021
    CD20
    |
    CD20 positive
    |
    Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • cyclophosphamide intravenous • ETBX-061 • NK92-CD16-158V
    Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (NCT04616209)
    Phase 1/2
    Precision Biotech Taiwan Corp.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/15/2020
    Primary completion :
    12/30/2027
    Completion :
    12/31/2027
    HLA-DRB1 • HLA-B • HLA-C
    |
    PB103
    A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (NCT05674526)
    Phase 1
    Wugen, Inc.
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    05/21/2024
    Primary completion :
    09/30/2025
    Completion :
    06/01/2026
    EGFR • BRAF
    |
    BRAF V600E • BRAF V600 • EGFR expression • RAS mutation
    |
    Erbitux (cetuximab) • WU-NK-101
    Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML (NCT04220684)
    Phase 1
    Sumithira Vasu
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/11/2020
    Primary completion :
    10/22/2024
    Completion :
    12/31/2025
    IL21
    |
    cytarabine • azacitidine • decitabine • fludarabine IV • SAR445419
    An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NCT06693973)
    Phase 1
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    11/19/2024
    Initiation :
    12/27/2023
    Primary completion :
    01/13/2026
    Completion :
    01/13/2026
    CD20
    |
    CD20 positive
    Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma (NCT01745588)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    12/01/2012
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CD34
    |
    dexamethasone • pomalidomide
    Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (NCT05922930)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    10/11/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    BRCA1 • BRCA2 • TACSTD2
    |
    BRCA2 mutation • BRCA1 mutation • TROP2 expression
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK
    Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 (NCT06083883)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    03/27/2024
    Primary completion :
    11/30/2026
    Completion :
    11/30/2028
    HLA-A • CTAG1B • SSX1
    |
    HLA-A*02
    |
    cyclophosphamide • fludarabine IV
    Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma (NCT06066359)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    11/30/2023
    Primary completion :
    08/31/2026
    Completion :
    08/31/2028
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02
    |
    cyclophosphamide • fludarabine IV
    First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (TCD17197) (NCT05086315)
    Phase 1/2
    Sanofi
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    12/08/2021
    Primary completion :
    12/11/2025
    Completion :
    11/11/2026
    IL3RA
    |
    bexatamig (IPH6101)
    Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) (NCT05883449)
    Phase 2
    Affimed GmbH
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    10/10/2023
    Primary completion :
    04/30/2026
    Completion :
    11/30/2027
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)